Citation: | NIU Kai-xuan, WU Shu-lu, LIU Cheng, DENG Xi-ming. Clinical value of serum amyloid A and interleukin-6 in the diagnosis and severity evaluation of sepsis[J]. Chinese Journal of General Practice, 2022, 20(9): 1484-1487. doi: 10.16766/j.cnki.issn.1674-4152.002629 |
[1] |
TAN M C, LU Y X, JIANG H, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis[J]. J Cell Biochem, 2019, 120(4): 5852-5859. doi: 10.1002/jcb.27870
|
[2] |
HUANG M, CAI S L, SU J Q. The pathogenesis of sepsis and potential therapeutic targets[J]. Int J Mol Sci, 2019, 20(21): 5376. doi: 10.3390/ijms20215376
|
[3] |
中国中西医结合学会检验医学专业委员会. 血清淀粉样蛋白A在感染性疾病中临床应用的专家共识[J]. 中华检验医学杂志, 2019, 42(3): 186-192.
Laboratory Medicine Committee of Chinese Association of Integrated Traditional Chinese and Western Medicine. Expert consensus on clinical application of serum amyloid A in infectious diseases[J]. Chinese Journal of Laboratory Medicine, 2019, 42(3): 186-192.
|
[4] |
HU P Y, CHEN Y L, PANG J M, et al. Association between IL-6 polymorphisms and sepsis[J]. Innate Immun, 2019, 25(8): 465-472. doi: 10.1177/1753425919872818
|
[5] |
孙晓琪, 刘贤英, 陈颖, 等. 血清降钙素原在脓毒症临床诊断中的应用研究[J]. 中华医院感染学杂志, 2019, 29(14): 2095-2098. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201914006.htm
SUN X Q, LIU X Y, CHEN Y, et al. Clinical value of serum procalcitonin in diagnosis of sepsis[J]. Chinese Journal of Nosocomiology, 2019, 29(14): 2095-2098. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201914006.htm
|
[6] |
SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. doi: 10.1001/jama.2016.0287
|
[7] |
RUDD K E, JOHNSON S C, AGESA K M, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: 10.1016/S0140-6736(19)32989-7
|
[8] |
QU J Y, FENG P, LUO Y, et al. Impact of hepatic function on serum procalcitonin for the diagnosis of bacterial infections in patients with chronic liver disease: A retrospective analysis of 324 cases[J]. Medicine (Baltimore), 2016, 95(30): e4270. DOI: 10.1097/MD.0000000000004270.
|
[9] |
TRENCHEVSKA O, YASSINE H N, BORGES C R, et al. Development of quantitative mass spectrometric immunoassay for serum amyloid A[J]. Biomarkers, 2016, 21(8): 743-751. doi: 10.1080/1354750X.2016.1201533
|
[10] |
曹琳, 宋晓文, 任金来, 等. 血清淀粉样蛋白A的研究进展[J]. 安徽医药, 2019, 23(2): 221-224. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYY201902004.htm
CAO L, SONG X W, REN J L, et al. Advances in research into serum amyloid A[J]. Anhui Medical and Pharmaceutical Journal, 2019, 23(2): 221-224. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYY201902004.htm
|
[11] |
DE BUCK M, GOUWY M, WANG J M, et al. Structure and expression of different serum amyloid A (SAA) vari-ants and their concentration-dependent functions during host insults[J]. Curr Med Chem, 2016, 23(17): 1725-1755. doi: 10.2174/0929867323666160418114600
|
[12] |
ROSE-JOHN S. Interleukin-6 family cytokines[J]. Cold Spring Harb Perspect Biol, 2018, 10(2): a028415. DOI: 10.1101/cshperspect.a028415.
|
[13] |
SONG J, PARK D W, MOON S, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: A prospective controlled study according to the Sepsis-3 definitions[J]. BMC Infect Dis, 2019, 19(1): 968. doi: 10.1186/s12879-019-4618-7
|
[14] |
HOU T Y, HUANG D H, ZENG R, et al. Accuracy of serum interleukin (IL)-6 in sepsis diagnosis: A systematic review and meta-analysis[J]. Int J Clin Exp Med, 2015, 8(9): 15238-15245.
|
[15] |
宫榭阳, 徐鹏, 葛长宇, 等. IL-6在卵巢癌中的研究进展[J]. 中华全科医学, 2019, 17(3): 455-458. doi: 10.16766/j.cnki.issn.1674-4152.000707
GONG X Y, XU P, GE C Y, et al. Research progress on IL-6 in ovarian cancer[J]. Chinese Journal of General Practice, 2019, 17(3): 455-458. doi: 10.16766/j.cnki.issn.1674-4152.000707
|
[16] |
PIERRAKOS C, VINCENT J L. Sepsis biomarkers: A review[J]. Crit Care, 2010, 14(1): R15. DOI: 10.1186/cc8872.
|
[17] |
PIERRAKOS C, VELISSARIS D, BISDORFF M, et al. Biomarkers of sepsis: Time for a reappraisal[J]. Crit Care, 2020, 24(1): 287. doi: 10.1186/s13054-020-02993-5
|
1. | 王林娜,张靖辉. 血清淀粉样蛋白A、白介素6、肿瘤坏死因子α及微小RNA在脓毒症并发急性肾损伤患儿中的表达及预后评估价值研究. 中国全科医学. 2025(03): 293-298 . ![]() | |
2. | 陈晓蕾,吴卉卉,张其霞,木晶晶,吴晓晓. 智能预警系统在脓毒症休克患者集束化治疗中的应用效果. 中华全科医学. 2025(01): 140-142+152 . ![]() | |
3. | 朱婷,董青利. 血清降钙素原、血清淀粉样蛋白A及白细胞介素-6水平对肝硬化合并腹水感染的诊断价值. 临床医学研究与实践. 2024(08): 89-92 . ![]() | |
4. | 郑枫,田文俊. 输尿管软镜联合负压吸引鞘术后无管化对上尿路结石患者应激及炎症反应的影响. 中华全科医学. 2024(04): 622-624+641 . ![]() | |
5. | 李红梅,陈正徐,高婉卿. 动脉血乳酸联合血清淀粉样蛋白A水平对脓毒症患儿发生休克的预测价值. 中国医药导报. 2024(08): 111-114 . ![]() | |
6. | 武登峰,杜云波,黄苏平. 查尔森合并症指数、动脉血氨、Toll样受体4水平与严重多发伤合并脓毒症患者病情的关系及其死亡风险预测价值. 临床内科杂志. 2024(06): 393-396 . ![]() | |
7. | 王成裕,张翼凤,刘建辉. PCT、SAA、CRP、IL-6与脓毒症患者病情严重程度及预后的相关性. 中国医药指南. 2024(26): 37-40 . ![]() | |
8. | 于天良,沈丽梅. 血清PCT、SAA及ACE2对非小细胞肺癌患者化疗期间肺部感染的鉴别诊断价值分析. 中华养生保健. 2024(23): 192-196 . ![]() | |
9. | 鲁杏,方长太,李晓倩,陈园园,查佳安. APACHEⅡ评分、IL-6与T淋巴细胞亚群联合构建脓毒症病情严重程度的预测模型. 中国临床研究. 2024(11): 1705-1708 . ![]() | |
10. | 赖思敏,于婵,吴梦珠,汤展宏. 血清IL-6、hs-CRP、SAA与老年脓毒症患者急性肺损伤程度的关系及预后评估. 中国临床研究. 2024(11): 1700-1704 . ![]() | |
11. | 王勇,张华,谭兵,沙前坤. 虎黄烧伤搽剂联合头孢类抗菌药物治疗急性创伤临床观察. 中国药业. 2023(03): 102-105 . ![]() | |
12. | 肖楠,赵秀英. 器官移植感染的精准快速实验诊断. 实用器官移植电子杂志. 2023(01): 1-5 . ![]() | |
13. | 周思颖,顾国嵘,慕婉晴,俞尧,陈东旭,孙湛,周燕南,姚晨玲. 细胞因子、经皮氧分压/吸入氧浓度联合危重评分对脓毒症患者进展为脓毒性休克及预后的预测价值. 中国临床医学. 2023(03): 426-431 . ![]() | |
14. | 林贞杰,姜波,何建花. NLR、IL-6联合肾脏阻力指数对脓毒性休克患者早期急性肾损伤的研究. 系统医学. 2023(10): 5-9 . ![]() | |
15. | 吴丽红,王林华,林琳,罗莉,史大治. 血必净注射液对脓毒症并发急性肾损伤疗效的Meta分析. 中国临床研究. 2023(10): 1474-1480 . ![]() | |
16. | 周科,杜贤荣,冯建宏. 脓毒症患者预后与红细胞体积分布宽度和中性粒细胞/淋巴细胞比值的关系. 中国临床研究. 2023(10): 1500-1503+1508 . ![]() |